Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists
- Bioorg Med Chem Lett. 2015 Mar 15;25(6):1196-205. doi: 10.1016/j.bmcl.2015.01.066.
- 1. Metabolic Diseases Chemistry, Bristol-Myers Squibb Research and Development (R&D), Princeton, NJ 08543-5400, USA.
- 2. Discovery Analytical Sciences, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
- 3. Metabolic Diseases Biology, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
- 4. Lead Evaluation, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
- 5. Metabolism and Pharmacokinetics, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
- 6. Computer-Assisted Drug Design, Bristol-Myers Squibb R&D, Princeton, NJ 08543-5400, USA.
The design, synthesis and structure-activity relationships of a novel series of 3,4-disubstituted pyrrolidine acid analogs as PPAR ligands is outlined. In both the 1,3- and 1,4-oxybenzyl pyrrolidine acid series, the preferred stereochemistry was shown to be the cis-3R,4S isomer, as exemplified by the potent dual PPARα/γ agonists 3k and 4i. The N-4-trifluoromethyl-pyrimidinyl pyrrolidine acid analog 4i was efficacious in lowering fasting glucose and triglyceride levels in diabetic db/db mice.